

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TATA Health International Holdings Limited

TATA 健康國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1255)

INSIDE INFORMATION WINDING-UP PETITION

This announcement is made by TATA Health International Holdings Limited (the “**Company**”) under Rules 13.09(1) and 13.25(1)(b) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

On 11 August 2026, the Company was made aware that a petition (the “**Petition**”) was filed on 11 August 2026 by a former independent non-executive director of the Company, Mr. Tao Chi Keung (the “**Petitioner**”) against the Company in the High Court of the Hong Kong Special Administrative Region (the “**High Court**”) for an order that the Company be wound up by the High Court (the “**Order**”). The Petition was filed against the Company for failure to pay the outstanding director’s emolument in the sum of HK\$139,150.68 (the “**Claim**”).

The Petitioner was appointed as an independent non-executive director of the Company on 20 October 2023 and resigned with effect from 13 June 2025. The period of the Petitioner’s appointment took place before the appointment of the current board of directors of the Company (the “**Board**”). The current Board does not know the Petitioner and has not worked with the Petitioner before. The Board is currently conducting an assessment of the then performance of the Petitioner as the Company’s independent non-executive director as well as the remuneration payable to him. Given that the Claim is not of a significant amount, the Board believes that this can be resolved and that the Order will not be granted. In any event, the Company is in the course of seeking legal advice in respect of the Petition and will take all necessary actions to protect its legal rights.

However, in light of the Petition, the Board may wish to remind shareholders and/or potential investors of the Company as to the following:

In accordance with section 182 of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), if the Company is ultimately wound up as a result of the Petition, any disposition of the property directly held by the Company, including things in action, and any transfer of shares, or alteration in the status of the members of the Company, after the commencement of the winding up, namely the date of the presentation of the Petition (i.e., 11 August 2026) (the “**Commencement Date**”), will be void unless a validation order is obtained from the High Court. Any disposition made on or after the Commencement Date will not be affected if the Petition is subsequently struck out, dismissed or permanently stayed.

The transfer of the shares in the Company made on or after the Commencement Date would be void absent the validation order from the High Court if the Company is ultimately wound up. In view of the uncertainties that may arise in relation to the transfer of shares of the Company, by the circular dated 28 December 2016 issued by Hong Kong Securities Clearing Company Limited (“**HKSCC**”) in relation to the transfer of the shares of listed issuers after a winding-up petition has been presented, HKSCC may, at any time, and without notice, exercise its powers under the General Rules of Central Clearing and Settlement System (“**CCASS**”) to temporarily suspend any of its services in respect of shares of the Company for participant(s) who conduct share transfers through HKSCC (“**Participant(s)**”). This may include the suspension of acceptance of deposits of share certificates of the Company into CCASS. The share certificates of the Company received by HKSCC but not re-registered in HKSCC Nominee Limited’s name will be returned to the relevant Participant. HKSCC shall reserve the right to reverse any credit granted to such Participant by debiting the relevant securities from its CCASS account. These measures would generally cease to apply from the date when the Petition has been dismissed or permanently stayed, or the Company has obtained the necessary validation order from the High Court.

The filing of the Petition does not represent the successful winding up of the Company by the Petitioner. No winding-up order has been granted by the High Court to wind up the Company as at the date of this announcement. The Petition is to be heard by the High Court at 10:00 a.m. on Wednesday, 21 October 2026.

The Company will keep its shareholders and investors informed of any significant development in relation to the Petition as and when appropriate.

Shareholders and/or potential investors of the Company are reminded to exercise caution when dealing in the securities of the Company.

By Order of the Board
TATA Health International Holdings Limited
Zhang Ming Qi
Executive Director

Hong Kong, 17 August 2026

As at the date of this announcement, the board of directors of the Company comprises an executive director, namely, Mr. Zhang Ming Qi; a non-executive Director, namely, Mr. Chen Qi; and four independent non-executive directors, namely, Ms. Huang Lin, Mr. Li Liang, Mr. Du Jianfeng and Mr. Tan Kaiguo.